Press Release | July 23, 2019 | Human Health, Medicare Part D, Cost & Value of Biopharmaceuticals, Out-Of-Pocket Costs
Washington, DC (July 23, 2019) – Following the release of the Senate Finance Committee’s drug pricing proposal, Tom DiLenge, the Biotechnology Innovation Organization’s President of Advocacy, Law & Public Policy Division issued the following statement:
“While we’re pleased that the…